Let's Discuss Free Meds for Long-Covid sufferers: A Call from the GP Association
Advocacy for Complimentary Pharmaceuticals for Individuals Struggling with Long-Covid by Primary Care Physicians - Long-term COVID patients advocated for by medical professionals call for provision of complimentary medications
Listen up, folks! Long-Covid patients are totting up the costs for their health, and it's freakin' ridiculous! As it stands, they're forking out their hard-earned cash for the 'off-label use' of medications, according to Markus Beier, chairman of the General Practitioners' Association, who spilled the beans in the Rheinische Post.
And, he ain't mincing his words, calling for a swift change in this unfair system. This dude is downright serious: "This needs to change quickly!" he hollered. In case you didn't know, there's no officially approved medication for Long-Covid currently, but that's a different story for another time.
The recent announcement from the new Federal Research Minister, Dorothee Bär (CSU), is a step in the right direction. She's gearing up to increase research efforts on Long-Covid, and how about that, she intends to partner with Health Minister Nina Warken (CDU) for a united front.
Beier is digging the vibe of increased investment in research for Long-Covid victims, calling it the "central approach to helping those affected as best as possible." That's just plain common sense, right?
While the German government has yet to announce plans for free medications for Long-Covid patients, the increasing emphasis on research and collaboration indicates a proactive approach in finding a solution. The economic impact of Long-Covid has already cost Germany a small fortune, with estimates putting the price tag at billions of euros in loss of productivity and increased healthcare costs.
Add to that the growing focus on research in Germany, highlighted by events like the 2nd Long COVID Symposium hosted by the German Centers for Health Research (DZG), where top-notch research experts convene to exchange ideas and try to crack the Long-Covid nut. International conferences focused on chronic conditions related to COVID-19, such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), are also underway in Germany.
So, while the specifics of free medication for Long-Covid patients are still up in the air, the writing's on the wall: the German government and research institutions are getting serious about addressing Long-Covid and its impact on public health and the economy.
Stay tuned, folks. This story's far from over!
[1] https://www.dsge-ev.de/corona-outbreak-impacts-on-german-economy/[2] https://dzg.de/corona-symposium/[3] https://www.rheinische-post.de/wirtschaft/gesundheit/a44560167/long-covid-bekaeMPFe-Medikation-gesundheitsexperten-mit-drohender-Verbraucherinsel.html[4] https://www.funder-db.de/en/project/covid-didactic/5264054[5] https://www.medizin.uni-greifswald.de/klinikum/ku-aktuelles/med-presseportal/beitrag/45912_Greifswald_veranstaltet_internationalen_Wissenschaftlerkreis_fuer_ME_und_MECFS (Although this is about ME/CFS, it provides an idea of the collaborative efforts underway in Germany)
EC countries could consider following Germany's proactive approach in addressing Long-Covid and its impact on public health and the economy, especially in terms of investing in science, research, and health-and-wellness, with a focus on mental-health and therapies-and-treatments for Long-Covid sufferers.
The science community, including health policy makers, could collaborate and exchange ideas at international conferences, such as the 2nd Long COVID Symposium in Germany, to find solutions for chronic conditions related to COVID-19, like Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).
